MCID: OST115
MIFTS: 44

Osteonecrosis of the Jaw

Categories: Bone diseases, Oral diseases, Rare diseases

Aliases & Classifications for Osteonecrosis of the Jaw

MalaCards integrated aliases for Osteonecrosis of the Jaw:

Name: Osteonecrosis of the Jaw 59

Classifications:



External Ids:

Orphanet 59 ORPHA399293
UMLS via Orphanet 74 C2711248
ICD10 via Orphanet 34 K10.2

Summaries for Osteonecrosis of the Jaw

MalaCards based summary : Osteonecrosis of the Jaw is related to osteonecrosis and periodontal disease. An important gene associated with Osteonecrosis of the Jaw is CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Zoledronic acid and Alendronate have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and breast, and related phenotype is renal/urinary system.

Wikipedia : 76 Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws (the... more...

Related Diseases for Osteonecrosis of the Jaw

Diseases related to Osteonecrosis of the Jaw via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 32.4 CYP2C8 FDPS VEGFA
2 periodontal disease 30.5 DEFB1 DEFB4A IL17A
3 arthritis 30.3 HLA-DQB1 HLA-DRB1 IL17A TGFB1
4 rheumatoid arthritis 30.2 HLA-DQB1 HLA-DRB1 IL17A TGFB1 VEGFA
5 osteoporosis 10.8
6 myeloma, multiple 10.8
7 prostate cancer 10.6
8 breast cancer 10.5
9 osteomyelitis 10.4
10 cerebrotendinous xanthomatosis 10.4
11 periodontitis 10.3
12 bone disease 10.2
13 bone resorption disease 10.2
14 corneal abscess 10.2 DEFB1 DEFB4A
15 endophthalmitis 10.2 DEFB1 VEGFA
16 bone mineral density quantitative trait locus 8 10.2
17 bone mineral density quantitative trait locus 15 10.2
18 diabetes mellitus 10.2
19 thrombophilia 10.2
20 fasciitis 10.2
21 necrotizing fasciitis 10.2
22 limbic encephalitis with lgi1 antibodies 10.1 HLA-DQB1 HLA-DRB1
23 central nervous system vasculitis 10.1 HLA-DRB1 IL17A
24 narcolepsy 2 10.1 HLA-DQB1 HLA-DRB1
25 autoimmune polyglandular syndrome type 3 10.1 HLA-DQB1 HLA-DRB1
26 hypersomnia 10.1 HLA-DQB1 HLA-DRB1
27 vulvovaginal candidiasis 10.1 DEFB1 DEFB4A
28 chronic inflammatory demyelinating polyradiculoneuropathy 10.1 HLA-DRB1 IL17A
29 metal allergy 10.1 HLA-DQB1 HLA-DRB1
30 lichen planopilaris 10.1 HLA-DQB1 HLA-DRB1
31 type ii mixed cryoglobulinemia 10.1 HLA-DQB1 HLA-DRB1
32 cystic echinococcosis 10.1 HLA-DRB1 IL17A
33 beryllium disease 10.1 HLA-DQB1 HLA-DRB1
34 intestinal disease 10.1 DEFB4A IL17A VEGFA
35 recurrent respiratory papillomatosis 10.1 HLA-DQB1 HLA-DRB1
36 narcolepsy 1 10.1 HLA-DQB1 HLA-DRB1
37 chronic beryllium disease 10.1 HLA-DQB1 HLA-DRB1
38 lichen sclerosus 10.1 HLA-DQB1 HLA-DRB1
39 whipple disease 10.1 HLA-DQB1 HLA-DRB1
40 pityriasis rosea 10.1 HLA-DQB1 HLA-DRB1
41 pediatric multiple sclerosis 10.1 HLA-DQB1 HLA-DRB1
42 microscopic colitis 10.1 HLA-DQB1 HLA-DRB1
43 colorectal cancer 10.1
44 renal cell carcinoma, nonpapillary 10.1
45 brittle bone disorder 10.1
46 crohn's disease 10.1
47 hepatitis 10.1
48 fibrous dysplasia 10.1
49 kidney cancer 10.1
50 rapidly involuting congenital hemangioma 10.1

Graphical network of the top 20 diseases related to Osteonecrosis of the Jaw:



Diseases related to Osteonecrosis of the Jaw

Symptoms & Phenotypes for Osteonecrosis of the Jaw

MGI Mouse Phenotypes related to Osteonecrosis of the Jaw:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.1 CYP19A1 HLA-DQB1 IL17A SEMA4D TGFB1 VEGFA

Drugs & Therapeutics for Osteonecrosis of the Jaw

Drugs for Osteonecrosis of the Jaw (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
2
Alendronate Approved Phase 4,Phase 2 66376-36-1, 121268-17-5 2088
3 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Hormones Phase 4
6
Denosumab Approved Phase 3,Phase 1,Phase 2 615258-40-7
7
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
8
Gemcitabine Approved Phase 3 95058-81-4 60750
9
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
10
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
11
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
12 Tocotrienol Investigational Phase 3 6829-55-6
13 Mitogens Phase 2, Phase 3,Not Applicable
14 Micronutrients Phase 3,Phase 2
15 Vitamins Phase 3,Phase 2
16 Trace Elements Phase 3,Phase 2
17 Tocopherols Phase 3
18 Vasodilator Agents Phase 3
19 Radiation-Protective Agents Phase 3
20 Tocotrienols Phase 3
21 Phosphodiesterase Inhibitors Phase 3
22 Protective Agents Phase 3
23 Free Radical Scavengers Phase 3
24 Antioxidants Phase 3
25 Platelet Aggregation Inhibitors Phase 3
26
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
27
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
28
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
29
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
30
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
32
Doxil Approved June 1999 Phase 2 31703
33 Antibiotics, Antitubercular Phase 2,Not Applicable
34 Anti-Bacterial Agents Phase 2,Not Applicable
35 Anti-Ulcer Agents Phase 2
36 Ergocalciferols Phase 2
37 Antacids Phase 2
38 Calciferol Phase 2
39 Gastrointestinal Agents Phase 2,Phase 1
40 Calcium, Dietary Phase 2
41 Vitamin D2 Phase 2
42 Antineoplastic Agents, Alkylating Phase 2
43 Alkylating Agents Phase 2
44 Antimitotic Agents Phase 2
45 Antirheumatic Agents Phase 2
46 Immunologic Factors Phase 2
47 Topoisomerase Inhibitors Phase 2
48 Immunosuppressive Agents Phase 2
49 Antibodies, Monoclonal Phase 1, Phase 2
50 Immunoglobulins Phase 1, Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
2 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4 Alendronate
3 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
4 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Completed NCT00523341 Phase 3
5 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Completed NCT00869206 Phase 3 zoledronic acid
6 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
7 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) Recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
8 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
9 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw Not yet recruiting NCT03390777 Phase 2, Phase 3
10 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed NCT00996801 Phase 2 MK-5442;Placebo to MK-5442;Alendronate Sodium;Vitamin D3;Calcium carbonate;Placebo to Alendronate
11 Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers Completed NCT01367288 Phase 2 Zometa + Neoadjuvant therapy;Neoadjuvant therapy
12 The Efficacy of Denosumab in Active Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
13 Reduced Dose-density of Denosumab for Unresectable GCTB Not yet recruiting NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
14 Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates Completed NCT00462098 Phase 1
15 Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis Recruiting NCT02566681 Phase 1
16 Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer Terminated NCT00892242 Phase 1 Zoledronic acid
17 Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay Unknown status NCT02218554 Not Applicable
18 Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction Unknown status NCT02198001 Not Applicable tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
19 CONDOR Study of Osteonecrosis of the Jaws (TMJ) Completed NCT01130389
20 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
21 Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Completed NCT01998607
22 DPBRN Retrospective Cohort Study of Osteonecrosis of the Jaw Completed NCT01201330
23 Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis Completed NCT00601068
24 Use of Topical Phenytoin in Bisphosphonate-related Osteonecrosis of the Mandible Completed NCT03269214 Not Applicable Topical Phenytoin 5%
25 Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging Completed NCT00592982
26 Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC Completed NCT01062503 Zoledronic acid
27 Medication-related Osteonecrosis of the Jaw (MRONJ) Registry Recruiting NCT02932501
28 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Recruiting NCT03418454
29 Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use Recruiting NCT01875458
30 Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction Recruiting NCT02661139
31 HBOT Late Radiation Tissue Injury Recruiting NCT02425215
32 Osteonecrosis of the Jaw (ONJ) Case Registry Active, not recruiting NCT01666106
33 Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid Active, not recruiting NCT01967160
34 S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Active, not recruiting NCT00874211
35 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study Active, not recruiting NCT00858585
36 Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques Terminated NCT02747173
37 Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid Withdrawn NCT02069340 Not Applicable zoledronic acid

Search NIH Clinical Center for Osteonecrosis of the Jaw

Genetic Tests for Osteonecrosis of the Jaw

Anatomical Context for Osteonecrosis of the Jaw

MalaCards organs/tissues related to Osteonecrosis of the Jaw:

41
Bone, Prostate, Breast, Bone Marrow, T Cells, Kidney, Lung

Publications for Osteonecrosis of the Jaw

Articles related to Osteonecrosis of the Jaw:

(show top 50) (show all 1001)
# Title Authors Year
1
Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. ( 29955628 )
2018
2
Comment on: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29799056 )
2018
3
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )
2018
4
Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. ( 29211870 )
2018
5
Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. ( 29870295 )
2018
6
Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. ( 29729428 )
2018
7
Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw. ( 29422306 )
2018
8
Machine learning to predict the occurrence of bisphosphonate-related osteonecrosis of the jaw associated with dental extraction: A preliminary report. ( 29698784 )
2018
9
Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. ( 29802059 )
2018
10
Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. ( 29325851 )
2018
11
Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. ( 29747794 )
2018
12
Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-NaA^ve Patient: A Comprehensive Review of the Literature. ( 29850569 )
2018
13
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. ( 29861164 )
2018
14
Comment on "Nasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw" by Lemound etA al. ( 29902417 )
2018
15
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. ( 29289789 )
2018
16
Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. ( 29408511 )
2018
17
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? ( 29860712 )
2018
18
Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw. ( 29857915 )
2018
19
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. ( 29713913 )
2018
20
Authors' reply: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29796683 )
2018
21
Medication-related osteonecrosis of the jaw, osteoradionecrosis, and osteomyelitis: A comparative histopathological study. ( 29723337 )
2018
22
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. ( 29694412 )
2018
23
Duration of treatment with bisphosphonates at the time of osteonecrosis of the jaw onset in patients with rheumatoid arthritis. Review. ( 29325766 )
2018
24
Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings. ( 29952657 )
2018
25
New method of alloplastic reconstruction of the mandible after subtotal mandibulectomy for medication-related osteonecrosis of the jaw. ( 29751943 )
2018
26
Patients' osteometabolic control improves the management of medication-related osteonecrosis of the jaw. ( 29249520 )
2018
27
Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw. ( 29224060 )
2018
28
CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. ( 29365278 )
2018
29
Treatment of pathologic fractures of the mandible in stage III medication-related osteonecrosis of the jaw-an observational study. ( 29885852 )
2018
30
WITHDROWN: Osteonecrosis of the jaw in patients traited by denosumab for malignant bone disease: Descriptive study on 9 cases ( 29680853 )
2018
31
Necrotizing fasciitis as a complication of osteonecrosis of the jaw related to oral bisphosphonate application in a patient with osteoporosis: a case report. ( 30288621 )
2018
32
Descending necrotizing mediastinitis after sequestrectomy in a patient with bisphosphonate-induced osteonecrosis of the jaw: A case report. ( 30101025 )
2018
33
Comparison of the histopathological characteristics of osteomyelitis, medication-related osteonecrosis of the jaw, and osteoradionecrosis. ( 30054185 )
2018
34
Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study. ( 30194738 )
2018
35
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology. ( 30200393 )
2018
36
Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study. ( 30211221 )
2018
37
Development of Medication-Related Osteonecrosis of the Jaw After Extraction of Teeth With Experimental Periapical Disease. ( 30218655 )
2018
38
Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses. ( 30220314 )
2018
39
Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. ( 30249535 )
2018
40
Systematic review and meta-analysis of risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: Approaches and strategies. ( 30262125 )
2018
41
Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw. ( 30276516 )
2018
42
Cytokine Mixtures Mimicking Secretomes From Mesenchymal Stem Cells Improve Medication-Related Osteonecrosis of the Jaw in a Rat Model. ( 30283893 )
2018
43
Medication-related osteonecrosis of the jaw: An institution's experience. ( 30296919 )
2018
44
The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. ( 30306086 )
2018
45
A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw. ( 30327979 )
2018
46
Life threatening bleeding from an osteonecrosis of the jaw: Are bisphosphonates safe in irradiated head and neck cancer patients? ( 30344138 )
2018
47
Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. ( 30353228 )
2018
48
Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. ( 30393090 )
2018
49
Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw. ( 30402414 )
2018
50
Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. ( 30406309 )
2018

Variations for Osteonecrosis of the Jaw

Expression for Osteonecrosis of the Jaw

Search GEO for disease gene expression data for Osteonecrosis of the Jaw.

Pathways for Osteonecrosis of the Jaw

GO Terms for Osteonecrosis of the Jaw

Cellular components related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 DEFB1 DEFB103B DEFB4A IL17A SEMA4D TGFB1
2 clathrin-coated endocytic vesicle membrane GO:0030669 9.32 HLA-DQB1 HLA-DRB1
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-DQB1 HLA-DRB1
4 MHC class II protein complex GO:0042613 9.16 HLA-DQB1 HLA-DRB1
5 Golgi lumen GO:0005796 8.92 DEFB1 DEFB103B DEFB4A TGFB1

Biological processes related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.71 SEMA4D TGFB1 VEGFA
2 chemotaxis GO:0006935 9.69 DEFB1 DEFB103B DEFB4A
3 defense response GO:0006952 9.67 DEFB1 DEFB103B DEFB4A
4 defense response to Gram-positive bacterium GO:0050830 9.61 DEFB1 DEFB103B DEFB4A
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.58 SEMA4D TGFB1 VEGFA
6 mammary gland development GO:0030879 9.55 CYP19A1 TGFB1
7 defense response to Gram-negative bacterium GO:0050829 9.54 DEFB1 DEFB103B DEFB4A
8 positive regulation of protein complex assembly GO:0031334 9.52 TGFB1 VEGFA
9 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.48 TGFB1 VEGFA
10 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.46 HLA-DQB1 HLA-DRB1
11 antimicrobial humoral response GO:0019730 9.43 DEFB1 DEFB103B DEFB4A
12 positive chemotaxis GO:0050918 9.33 DEFB103B DEFB4A VEGFA
13 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.32 HLA-DQB1 HLA-DRB1
14 immune response GO:0006955 9.1 DEFB1 DEFB4A HLA-DQB1 HLA-DRB1 IL17A SEMA4D
15 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DQB1 HLA-DRB1

Molecular functions related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.61 IL17A TGFB1 VEGFA
2 peptide antigen binding GO:0042605 9.4 HLA-DQB1 HLA-DRB1
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.37 CYP19A1 CYP2C8
4 steroid hydroxylase activity GO:0008395 9.32 CYP19A1 CYP2C8
5 aromatase activity GO:0070330 9.26 CYP19A1 CYP2C8
6 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
7 chemoattractant activity GO:0042056 9.13 DEFB103B DEFB4A VEGFA
8 CCR6 chemokine receptor binding GO:0031731 8.8 DEFB1 DEFB103B DEFB4A

Sources for Osteonecrosis of the Jaw

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....